SNY News and Press, Sanofi From 04/16/24

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...

2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...

2024-04-09 14:15:55 ET More on Nurix, Sanofi, etc. Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi agrees to settle ~4K...

2024-04-09 05:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-05 13:00:48 ET More on Immunic Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Immunic Historical earnings data for Immunic Financial information for Immunic Read the full article on Seeking Alpha...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...

2024-04-03 17:45:51 ET French drugmaker Sanofi ( NASDAQ: SNY ) on Wednesday said it had agreed to settle about 4K lawsuits in all U.S. states outside of Del. over accusations that its Zantac heartburn drug caused cancer. ... Read the full article on Seeking Alpha Fo...

2024-04-03 15:00:03 ET Jasper Hellweg from Argus Research issued a price target of $55.00 for SNY on 2024-04-03 12:55:00. The adjusted price target was set to $55.00. At the time of the announcement, SNY was trading at $48. The overall price target consensus is at $48.07...

2024-03-31 21:35:02 ET More on Regeneron, Sanofi Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Sanofi: My Top Pick In Big Pharma Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) U.S. CDC warns...